1 序文
2 調査範囲と方法論
2.1 調査の目的
2.2 ステークホルダー
2.3 データソース
2.3.1 一次情報源
2.3.2 二次情報源
2.4 市場推定
2.4.1 ボトムアップ・アプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法
3 エグゼクティブ・サマリー
4 はじめに
4.1 概要
4.2 主要業界動向
5 世界のセファロスポリン市場
5.1 市場概要
5.2 市場パフォーマンス
5.3 COVID-19の影響
5.4 世代別市場構成
5.5 投与経路別市場構成比
5.6 用途別市場構成比
5.7 地域別市場構成比
5.8 市場予測
6 世代別市場構成比
6.1 第一世代
6.1.1 市場動向
6.1.2 市場予測
6.2 第二世代
6.2.1 市場動向
6.2.2 市場予測
6.3 第三世代
6.3.1 市場動向
6.3.2 市場予測
6.4 第4世代
6.4.1 市場動向
6.4.2 市場予測
6.5 第5世代
6.5.1 市場動向
6.5.2 市場予測
7 投与経路別市場内訳
7.1 注射剤
7.1.1 市場動向
7.1.2 市場予測
7.2 経口剤
7.2.1 市場動向
7.2.2 市場予測
8 用途別市場
8.1 呼吸器
8.1.1 市場動向
8.1.2 市場予測
8.2 皮膚感染症
8.2.1 市場動向
8.2.2 市場予測
8.3 耳感染症
8.3.1 市場動向
8.3.2 市場予測
8.4 尿路感染症
8.4.1 市場動向
8.4.2 市場予測
8.5 性感染症
8.5.1 市場動向
8.5.2 市場予測
8.6 その他
8.6.1 市場動向
8.6.2 市場予測
9 地域別市場内訳
9.1 アジア太平洋
9.1.1 市場動向
9.1.2 市場予測
9.2 欧州
9.2.1 市場動向
9.2.2 市場予測
9.3 北米
9.3.1 市場動向
9.3.2 市場予測
9.4 中東・アフリカ
9.4.1 市場動向
9.4.2 市場予測
9.5 中南米
9.5.1 市場動向
9.5.2 市場予測
10 SWOT分析
10.1 概要
10.2 長所
10.3 弱点
10.4 機会
10.5 脅威
11 バリューチェーン分析
12 ポーターズファイブフォース分析
12.1 概要
12.2 買い手の交渉力
12.3 供給者の交渉力
12.4 競争の程度
12.5 新規参入の脅威
12.6 代替品の脅威
13 価格分析
13.1 価格指標
13.2 価格構造
13.3 マージン分析
14 競争環境
14.1 市場構造
14.2 主要プレーヤー
14.3 主要プレーヤーのプロフィール
14.3.1 アラガン社
14.3.2 ブリストル・マイヤーズ スクイブ社
14.3.3 F.ホフマン・ラ・ロシュ社
14.3.4 グラクソ・スミスクライン plc
14.3.5 ルピン・リミテッド
14.3.6 Merck & Co.Inc.
14.3.7 ノバルティスインターナショナルAG（サンド）
14.3.8 ファイザー株式会社
14.3.9 サノフィ
14.3.10 テバ・ファーマシューティカル・インダストリーズ・リミテッド
14.3.11 アボット
14.3.12 サン・ファーマシューティカル・インダストリーズ・リミテッド

[図のリスト］
図1：世界：セファロスポリン市場：主な推進要因と課題
図2：世界：セファロスポリン市場：販売額（単位：億米ドル）、2019年～2024年
図3：世界：セファロスポリン市場：図3：セファロスポリンの世界市場：世代別構成比（単位：%）、2024年
図4：世界：セファロスポリン市場図4：セファロスポリンの世界市場：投与経路別構成比（%）、2024年
図5：セファロスポリンの世界市場：用途別構成比（%）、2024年セファロスポリンの世界市場：用途別構成比（%）、2024年
図6：セファロスポリンの世界市場：用途別構成比（単位：%）、2024年セファロスポリンの世界市場：地域別構成比（%）、2024年
図7: セファロスポリンの世界市場予測：販売額（単位：億米ドル）、2025年～2033年
図8：世界：セファロスポリン（第一世代）市場販売額（単位：百万USドル）、2019年・2024年
図9：世界：セファロスポリン（第一世代）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図10：世界：セファロスポリン（第二世代）市場：販売額（単位：百万米ドル）、2019年・2024年
図11：世界：セファロスポリン（第二世代）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図12：世界：セファロスポリン（第三世代）市場：販売額（単位：百万米ドル）、2019年・2024年
図13：世界：セファロスポリン（第三世代）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図14：世界：セファロスポリン（第四世代）市場：販売額（単位：百万米ドル）、2019年・2024年
図15：世界：セファロスポリン（第四世代）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図16：世界：セファロスポリン（第五世代）市場：販売額（単位：百万米ドル）、2019年・2024年
図17：世界：セファロスポリン（第五世代）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図18：世界：セファロスポリン（注射剤）市場販売額（単位：百万米ドル）、2019年および2024年
図19: セファロスポリン（注射剤）の世界市場予測：販売額（単位：百万米ドル）、2025年～2033年
図20: 世界: セファロスポリン（経口剤）市場：販売額（単位：百万米ドル）、2019年・2024年
図21: 世界のセファロスポリン(経口剤)市場予測：販売額（単位：百万米ドル）、2025年～2033年
図22: 世界: セファロスポリン（呼吸器系）市場：販売額（単位：百万USドル）、2019年・2024年
図23：世界：セファロスポリン（呼吸器系）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図24：世界：セファロスポリン（皮膚感染症）市場販売金額（単位：百万USドル）、2019年・2024年
図25：世界：セファロスポリン（皮膚感染症）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図26：世界：セファロスポリン（耳感染症）市場：販売金額（単位：百万USドル）、2019年・2024年
図27：世界：セファロスポリン（耳感染症）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図28：世界：セファロスポリン（尿路感染症）市場：販売額（単位：百万USドル）、2019年・2024年
図29：世界：セファロスポリン（尿路感染症）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図30：世界：セファロスポリン（性感染症）市場：販売額（単位：百万米ドル）、2019年・2024年
図31：世界：セファロスポリン（性感染症）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図32：世界：セファロスポリン（その他の用途）市場：販売額（単位：百万USドル）、2019年・2024年
図33：世界：セファロスポリン（その他の用途）市場予測：販売額（単位：百万米ドル）、2025年～2033年
図34：アジア太平洋地域セファロスポリン市場：販売金額（単位：百万米ドル）、2019年および2024年
図35：アジア太平洋地域のセファロスポリン市場予測：販売額（単位：百万米ドル）、2025年～2033年
図36：ヨーロッパ：セファロスポリン市場予測セファロスポリン市場販売額（単位：百万米ドル）、2019年および2024年
図37：欧州：セファロスポリン市場予測：2019年および2024年セファロスポリン市場予測：販売額（単位：百万米ドル）、2025年～2033年
図38：北米：セファロスポリン市場：2025-2033年セファロスポリン市場販売金額（単位：百万米ドル）、2019年および2024年
図39：北米：セファロスポリン市場予測セファロスポリン市場予測：販売額（単位：百万米ドル）、2025年～2033年
図40：中東およびアフリカ：セファロスポリン市場販売金額（単位：百万米ドル）、2019年および2024年
図41：中東およびアフリカ：セファロスポリンの市場予測：販売額（単位：百万米ドル）、2025年～2033年
図42：ラテンアメリカ：セファロスポリン市場販売額（単位：百万米ドル）、2019年および2024年
図43：ラテンアメリカ：セファロスポリン市場予測セファロスポリン市場予測：販売金額（単位：百万米ドル）、2025年～2033年
図 44：世界: セファロスポリン産業：SWOT分析
図 45：世界: セファロスポリン産業：バリューチェーン分析
図 46：世界：セファロスポリン産業：ポーターのファイブフォース分析

[表一覧］
表1：世界：セファロスポリン市場：主要産業ハイライト、2024年と2033年
表2：世界：セファロスポリン市場予測：世代別内訳（単位：百万米ドル）、2025年～2033年
表3：世界：セファロスポリンの市場予測：セファロスポリンの世界市場予測：投与経路別構成比（単位：百万米ドル）、2025-2033年
表4：セファロスポリンの世界市場予測：投与経路別構成比（単位：百万米ドル、2025-2033年用途別構成比（単位：百万米ドル）、2025-2033年
表5：セファロスポリンの世界市場予測：用途別構成比（単位：百万米ドル、2025年～2033年セファロスポリンの世界市場予測：地域別構成比（単位：百万米ドル）、2025-2033年
表6：世界のセファロスポリン市場構造
表7：世界のセファロスポリン市場：主要プレイヤー

The global cephalosporin market size reached USD 19.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 24.8 Billion by 2033, exhibiting a growth rate (CAGR) of 2.45% during 2025-2033. The market is experiencing steady growth driven by increasing antibiotic-resistant infections, the demand for effective and safer treatment options, ongoing research and development efforts to introduce new cephalosporin formulations, and rising awareness among healthcare professionals regarding their broad-spectrum antibiotic properties.

Cephalosporin Market Analysis:
Market Growth and Size: The global cephalosporin market is experiencing stable growth, driven by rising antibiotic-resistant infections, and is estimated to be valued at billions of dollars.
Technological Advancements: Ongoing technological advancements have led to the development of more efficient and safer cephalosporin antibiotics, enhancing their effectiveness and reducing side effects.
Industry Applications: Cephalosporins find applications in treating a wide range of bacterial infections, including respiratory, urinary tract, skin, and soft tissue infections, making them vital in the healthcare industry.
Geographical Trends: North America and Europe lead in cephalosporin consumption, driven by advanced healthcare infrastructure and stringent regulatory standards.
Competitive Landscape: Key players in the market include pharmaceutical companies such as GlaxoSmithKline, Pfizer, and Teva Pharmaceuticals, among others, competing to introduce innovative cephalosporin drugs.
Challenges and Opportunities: Challenges include antibiotic resistance and regulatory hurdles. Opportunities lie in expanding into emerging markets and addressing unmet medical needs.
Future Outlook: The cephalosporin market is expected to continue its growth trajectory, with a focus on novel drug development, expanding applications, and addressing global health challenges related to antibiotic resistance.

Cephalosporin Market Trends:
Increasing prevalence of bacterial infections

The global cephalosporin market is significantly driven by the rising prevalence of bacterial infections. Cephalosporins, being a class of antibiotics, are critical in treating various bacterial infections including pneumonia, strep throat, staph infections, tonsillitis, and sinusitis. The increasing incidence of these infections, particularly in densely populated and developing regions, necessitates the demand for effective antibiotics. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) report rising cases of bacterial infections, thereby fueling the growth of the cephalosporin market. This demand is further amplified by the growing awareness among people regarding health and hygiene, which leads to early diagnosis and treatment of such infections.

Advancements in product variants

Technological advancements in pharmaceuticals have led to the development of advanced generation cephalosporins with enhanced efficacy against a broader spectrum of bacteria. These newer generations are designed to overcome antibiotic resistance, a major concern in the medical community. For instance, third and fourth-generation cephalosporins offer improved activity against Gram-negative bacteria and are more effective in penetrating the outer membrane of these bacteria. The ongoing research and development in this sector are pivotal in driving the cephalosporin market. Pharmaceutical companies are investing heavily in R&D to develop novel cephalosporins that can address the challenge of drug-resistant bacterial strains, thus propelling the market growth.

Increasing awareness and government initiatives

There is a growing awareness about bacterial infections and the importance of effective treatment, supported by various government initiatives and healthcare programs. Governments across the globe are increasingly funding health initiatives that include awareness campaigns about the proper use of antibiotics and the dangers of antibiotic resistance. Such initiatives not only educate the public but also promote the use of effective antibiotics like cephalosporins. Additionally, government funding in healthcare infrastructure, especially in developing countries, is contributing to the accessibility and availability of advanced antibiotics, thereby driving the cephalosporin market.

Developing healthcare infrastructure

The expansion of healthcare infrastructure globally is a major factor contributing to the growth of the cephalosporin market. Improving healthcare facilities, especially in emerging economies, leads to better access to medical treatments and antibiotics. The increase in hospitals, clinics, and healthcare centers, coupled with improved diagnostic facilities, enables more effective treatment of bacterial infections. This expansion is not only limited to urban areas but also extends to rural regions, thereby increasing the reach of effective antibiotics like cephalosporins. The growing healthcare sector directly correlates with the increased demand for cephalosporins, as they are essential in treating various bacterial infections.

Cephalosporin Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, and regional levels for 2025-2033. Our report has categorized the market based on generation, route of administration, and application.

Breakup by Generation:

• First Generation
• Second Generation
• Third Generation
• Fourth Generation
• Fifth Generation

Third generation accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the generation. This includes first generation, second generation, third generation, fourth generation, and fifth generation. According to the report, third generation represented the largest segment.

First-generation cephalosporins constitute a significant segment of the cephalosporin market. These antibiotics are characterized by their broad-spectrum activity against Gram-positive bacteria and some Gram-negative bacteria. They are commonly used for the treatment of uncomplicated skin and soft tissue infections, urinary tract infections, and surgical prophylaxis. First-generation cephalosporins are valued for their efficacy in addressing common bacterial infections and are often preferred when narrower coverage is sufficient.

Second-generation cephalosporins represent another essential segment in the cephalosporin market. These antibiotics offer an expanded spectrum of activity compared to the first generation, with enhanced effectiveness against Gram-negative bacteria. They find application in treating respiratory tract infections, urinary tract infections, and intra-abdominal infections. Second-generation cephalosporins are valued for their ability to address a broader range of bacterial pathogens.

The third-generation cephalosporins constitute the largest and most significant segment in the cephalosporin market. They are known for their extended spectrum of activity, particularly against resistant Gram-negative bacteria. This segment includes antibiotics like ceftriaxone and cefotaxime, which are widely used in the treatment of severe infections such as pneumonia, meningitis, and complicated intra-abdominal infections. Third-generation cephalosporins are critical in modern healthcare for their effectiveness against challenging bacterial pathogens.

Fourth-generation cephalosporins represent an evolving segment of the market, known for their extended spectrum and increased stability against beta-lactamases. They are used to treat complicated infections, including hospital-acquired pneumonia and urinary tract infections. These antibiotics offer an alternative when higher resistance is encountered or when a broader spectrum is required.

Fifth-generation cephalosporins are the latest addition to the cephalosporin market, known for their unique spectrum of activity. They exhibit potent activity against multi-drug-resistant Gram-negative bacteria, including extended-spectrum beta-lactamase (ESBL)-producing strains. These antibiotics are employed in complex hospital settings where resistance patterns pose a significant challenge. Fifth-generation cephalosporins are a valuable tool in combating antibiotic resistance and addressing emerging bacterial threats.

Breakup by Route of Administration:

• Injection
• Oral

Injection holds the largest share in the industry

A detailed breakup and analysis of the market based on the route of administration have also been provided in the report. This includes injection and oral. According to the report, injection accounted for the largest market share.

The injection segment represents the leading market share. Cephalosporin antibiotics administered via injection are favored in critical healthcare settings, such as hospitals and clinics, due to their rapid and effective delivery directly into the bloodstream. This segment includes a wide range of injectable cephalosporin formulations, including intravenous (IV) and intramuscular (IM) injections, designed to combat various bacterial infections. The injection segment is particularly vital in treating severe infections, surgical prophylaxis, and cases where patients are unable to take oral medications. Factors driving the growth of this segment include the need for immediate therapeutic action, the precision of dosage, and the preference of healthcare professionals for injectable formulations, making it a cornerstone of the Cephalosporin market's success.

The oral segment in the market represents an essential component of the market, offering a convenient and patient-friendly mode of administration. Oral cephalosporins are prescribed for a wide range of less severe bacterial infections, including respiratory tract infections, urinary tract infections, and skin and soft tissue infections. This segment includes tablets, capsules, and oral suspensions, providing patients with options for self-administration and improved compliance with treatment regimens. The oral segment's growth is driven by factors such as ease of use, reduced healthcare costs associated with outpatient care, and the availability of numerous oral cephalosporin formulations catering to various infection types and patient profiles. It plays a crucial role in extending the accessibility of cephalosporin antibiotics to a broader population and contributes significantly to the overall Cephalosporin market.

Breakup by Application:

• Respiratory Tract
• Skin Infection
• Ear Infection
• Urinary Tract Infection
• Sexually Transmitted Infection
• Others

The report has provided a detailed breakup and analysis of the market based on the application. This includes respiratory tract, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others.

Respiratory tract infections encompass conditions like pneumonia, bronchitis, and sinusitis. Cephalosporin antibiotics are widely used in the treatment of respiratory tract infections due to their effectiveness against a broad range of bacterial pathogens commonly associated with these ailments. Their ability to target respiratory bacteria makes them a vital component in the arsenal of antibiotics used to combat respiratory infections, helping patients recover and breathe easier.

Skin infections, including cellulitis, abscesses, and impetigo, form another essential segment in the cephalosporin market. These infections can range from mild to severe and are often caused by bacteria such as Staphylococcus and Streptococcus species. Cephalosporin antibiotics are preferred in skin infection treatment due to their bactericidal properties, which effectively eliminate the causative agents, promoting healing and preventing the spread of infection.

Ear infections, both middle ear (otitis media) and external ear (otitis externa) infections, are a common health issue, particularly in children. Cephalosporin antibiotics are prescribed when the infection is severe or resistant to other treatments. Their ability to target the specific bacteria responsible for ear infections makes them a valuable choice in these cases, alleviating pain and discomfort while preventing complications.

Urinary tract infections (UTIs) are a prevalent health concern, especially among women. Cephalosporin antibiotics are used to treat complicated UTIs caused by multi-drug-resistant bacteria. Their effectiveness in eradicating urinary tract pathogens, such as Escherichia coli and Klebsiella species, ensures effective treatment and reduces the risk of recurrent infections.

Cephalosporin antibiotics play a crucial role in the treatment of certain sexually transmitted infections (STIs) like gonorrhea. Their use is essential to combat the increasing antibiotic resistance observed in some STI-causing bacteria, helping to prevent the spread of these infections and their associated complications.

Breakup by Region:

• Asia Pacific
• Europe
• North America
• Middle East and Africa
• Latin America

Asia Pacific leads the market, accounting for the largest cephalosporin market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.

In the North American cephalosporin market, characterized by well-established healthcare infrastructure and stringent regulatory standards, there is a robust demand for these antibiotics. Factors driving market growth include a high prevalence of antibiotic-resistant infections, a focus on advanced healthcare solutions, and significant investments in research and development. North America remains a prominent consumer of Cephalosporin antibiotics, with pharmaceutical companies actively innovating to meet the region's healthcare needs.

Europe's market is marked by a growing emphasis on healthcare quality and patient safety. The region's demand for Cephalosporin antibiotics is driven by an aging population, increased awareness of antibiotic-resistant infections, and government initiatives to curb the spread of such infections. European pharmaceutical companies are investing in research and development to produce innovative cephalosporin formulations, aligning with the region's commitment to superior healthcare standards.

Asia Pacific stands out as the largest segment in the global cephalosporin market. The region's dominance is attributed to its population size, rapid urbanization, and expanding healthcare access. The demand for cephalosporin antibiotics in Asia Pacific is driven by a high incidence of infectious diseases, increased healthcare spending, and a burgeoning pharmaceutical industry. Moreover, the region's manufacturers are gaining recognition for their role in the global supply chain, contributing to Asia Pacific's leading position in the market.

Latin America's market is witnessing steady growth due to improving healthcare infrastructure, rising healthcare expenditure, and a growing burden of infectious diseases. Pharmaceutical companies in the region are focusing on meeting the demand for cephalosporin antibiotics, particularly as awareness of antibiotic-resistant infections grows. Latin America is becoming an increasingly important player in the global market.

The Middle East and Africa region exhibit a growing demand for cephalosporin antibiotics, driven by factors such as population growth, urbanization, and efforts to combat infectious diseases. While the market in this region is smaller compared to others, it is expanding as healthcare infrastructure improves and healthcare professionals increasingly rely on cephalosporin antibiotics to treat a wide range of bacterial infections. This region represents a notable growth opportunity for cephalosporin manufacturers looking to diversify their market presence.

Leading Key Players in the Cephalosporin Industry:
Key players in the cephalosporin market are actively engaged in several strategic initiatives to maintain their competitive edge and meet the evolving healthcare demands. These initiatives include research and development efforts aimed at introducing novel Cephalosporin formulations with enhanced properties, such as improved efficacy and reduced side effects, aligning with the growing emphasis on patient safety and treatment effectiveness. Additionally, players are expanding their global market presence through partnerships, acquisitions, and collaborations with other pharmaceutical companies and research institutions to access new markets and leverage collective expertise. Ensuring compliance with regulatory standards and promoting sustainable manufacturing practices are also central to their strategies, underscoring their commitment to producing safe and environmentally responsible antibiotics.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Allergan Plc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Lupin Limited
• Merck & Co. Inc.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Sun Pharmaceutical Industries Limited

Key Questions Answered in This Report

1.What was the size of the global cephalosporin market in 2024?

2.What is the expected growth rate of the global cephalosporin market during 2025-2033?

3.What are the key factors driving the global cephalosporin market?

4.What has been the impact of COVID-19 on the global cephalosporin market?

5.What is the breakup of the global cephalosporin market based on the generation?

6.What is the breakup of the global cephalosporin market based on the route of administration?

7.What are the key regions in the global cephalosporin market?

8.Who are the key players/companies in the global cephalosporin market?